HUTCHMED (China) Limited (HCM.L)
| Previous Close | 296.00 |
| Open | 309.00 |
| Bid | 306.00 x 0 |
| Ask | 310.00 x 0 |
| Day's Range | 305.00 - 310.00 |
| 52 Week Range | 173.60 - 338.00 |
| Volume | |
| Avg. Volume | 82,082 |
| Market Cap | 2.638B |
| Beta (5Y Monthly) | 0.68 |
| PE Ratio (TTM) | 30.90 |
| EPS (TTM) | 0.10 |
| Earnings Date | Feb 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.99 |
Simply Wall St.HUTCHMED (China) (LON:HCM) shareholders are up 8.2% this past week, but still in the red over the last five years
It is a pleasure to report that the HUTCHMED (China) Limited ( LON:HCM ) is up 35% in the last quarter. But over the...
GlobeNewswireHUTCHMED Highlights Data to be Presented at AACR Congress 2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California. Initial preclinical data will be presented for HMPL-506, a novel, highly potent and d
- GlobeNewswire
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 — — First regulatory filing for fruquintinib for use in combination with a leading immune checkpoint inhibitor — HONG KONG, SHANGHAI, China & FLORHAM PARK, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX:1801) today jointly announce that the New Drug Applicati
